Axsome Therapeutics presented a range of data from its neuroscience pipeline at the NEI Congress 2024, focusing on Auvelity (AXS-05) for major depressive disorder (MDD) and solriamfetol for narcolepsy and obstructive sleep apnea (OSA). The presentations highlighted the efficacy, real-world usage, and cognitive benefits of these treatments.
Auvelity Demonstrates Efficacy in MDD
Pooled data from the GEMINI and ASCEND trials showed that Auvelity significantly improved MDD symptoms. Craig Chepke, MD, SUNY Upstate Medical University, presented data indicating robust efficacy in a broad patient population. Additional findings presented by Roger McIntyre, MD, University of Toronto, demonstrated that Auvelity improved anhedonia and interest-activity symptoms, leading to associated improvements in functional impairment. These results underscore Auvelity's potential to address core MDD symptoms beyond traditional measures.
Real-World Insights on Auvelity Usage
Two presentations focused on real-world experiences with Auvelity. One poster, led by Roger McIntyre, MD, examined treatment experiences and expectations based on symptom severity in MDD patients. Another, presented by Andrew Muzyk, MD, Campbell University, detailed real-world patient characteristics. These insights provide valuable context for clinicians using Auvelity in diverse patient populations.
Solriamfetol Benefits in Narcolepsy and OSA
Data on solriamfetol highlighted its effectiveness in managing excessive daytime sleepiness in patients with narcolepsy and OSA. A real-world study (SURWEY) presented by Ulf Kallweit, MD, University Witten/Herdecke, Germany, showed that solriamfetol was effective even in patients reporting anxiety and depression. These findings suggest that solriamfetol can be a valuable option for patients with comorbid conditions.
Cognitive Improvements with Solriamfetol
Two presentations by Yaroslav Winter, MD, University of Mainz, Germany, focused on the cognitive benefits of solriamfetol. One analysis of the SHARP clinical trial demonstrated that solriamfetol improved cognition in OSA patients with excessive daytime sleepiness and impaired cognition. The other presentation, using data from the SURWEY study, showed similar cognitive benefits in narcolepsy patients. These results support solriamfetol's role in addressing cognitive deficits associated with sleep disorders.
